Talbot Financial LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 6.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 94,183 shares of the biopharmaceutical company’s stock after acquiring an additional 5,950 shares during the period. Talbot Financial LLC’s holdings in Bristol-Myers Squibb were worth $4,873,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of BMY. ESL Trust Services LLC bought a new stake in Bristol-Myers Squibb during the first quarter worth about $27,000. LGT Financial Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 227 shares during the last quarter. MFA Wealth Advisors LLC acquired a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at $39,000. Fairman Group LLC bought a new stake in Bristol-Myers Squibb during the 4th quarter worth $42,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Bristol-Myers Squibb in the 2nd quarter worth about $42,000. 76.41% of the stock is currently owned by institutional investors.
Bristol-Myers Squibb Stock Down 1.8 %
Bristol-Myers Squibb stock opened at $52.48 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.16 and a debt-to-equity ratio of 2.86. The company has a market capitalization of $106.38 billion, a PE ratio of -16.93, a PEG ratio of 12.96 and a beta of 0.46. The firm’s fifty day moving average is $49.43 and its 200 day moving average is $46.34. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $57.65.
Bristol-Myers Squibb Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.57%. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the stock. TD Cowen lifted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a research report on Monday. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Jefferies Financial Group increased their price objective on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. BMO Capital Markets reiterated a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $53.43.
Get Our Latest Stock Report on BMY
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Further Reading
- Five stocks we like better than Bristol-Myers Squibb
- Golden Cross Stocks: Pattern, Examples and Charts
- These 3 Stocks Just Spiked—Buy the Rally or Sell the News?
- Compound Interest and Why It Matters When Investing
- Big Government Contracts Propel These 3 Defense Stocks Higher
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 3 Powerful ETFs for Income Seekers Looking to Maximize Gains
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.